PHARMACEUTICAL INJECTION FORM OF HYDROPHILIC CONJUGATE OF HYDROXYETHYLAMYLUM AND 2,6-DIISOBORNYL-4-METHYLPHENOL, METHOD FOR ITS PRODUCTION AND APPLICATIONS FOR CARDIOVASCULAR DISEASES TREATMENT Russian patent published in 2017 - IPC A61K31/05 A61K47/61 A61K9/08 A61P9/00 A61P7/00 A61P39/06 

FIELD: pharmacology.

SUBSTANCE: pharmaceutical injection form of hydrophilic conjugate of hydroxyethylamylum and 2,6-diisobornyl-4-methylphenol for cardiovascular diseases treatment contains a therapeutically effective amount of O-(4-hydroxy-3,5-di(1,7,7-trimethylbicyclo[2.2.1]hept-exo-2-yl)benzyl)oxy)ethyl)-O-(2-hydroxyethyl)-(1,4)-α-D-glucan (Dibornol-HEC) as an active ingredient. Sodium chloride, Tween 80, ascorbic acid, water for injection or saline in the amounts indicated in the claims are used as auxiliary components. In the method for pharmaceutical injection form preparation, the Dibornol-HEC substance is added to an aqueous solution of Tween 80 surfactant and mixed until the substance is dissolved completely and a clear solution is obtained, the water is distilled off under reduced pressure, ascorbic acid, sodium chloride, saline (water for injection) are added to the dry residue and mixed, the solution is adjusted to a concentration of 4.5-7.5% by the active Dibornol-HEC substance with saline (water for injection) and centrifuged, if necessary, the solution is filtered, the resulting drug solution is poured into glass vials or ampoules, which are sealed and packaged.

EFFECT: pharmaceutical injection form of the invention is stable.

2 cl, 1 tbl, 15 ex